The effect of trimoprostil (trimethyldesoxy prostaglandin E2) on the intrauterine pressure in women

• Published in: Clinical pharmacology and therapeutics Vol. 44; no. 2; p. 179
• Main Authors: Reele, S B, Nauss-Karol, C, Lusaitis, A A, Passe, S M
• Format: Journal Article
• Language: English
• Published: United States 01-08-1988
• Subjects: Adult; Analysis of Variance; Anti-Ulcer Agents - pharmacology; Clinical Trials as Topic; Dinoprostone - analogs & derivatives; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Menstrual Cycle; Middle Aged; Pressure; Prostaglandins E, Synthetic - administration & dosage; Prostaglandins E, Synthetic - adverse effects; Prostaglandins E, Synthetic - pharmacology; Time Factors; Uterine Contraction - drug effects; Uterus - drug effects
• DOI: 10.1038/clpt.1988.134
• ISSN: 0009-9236

Prostaglandin E2 is uterotonic. Trimoprostil, a prostaglandin E2 analog, is a gastric antisecretory and cytoprotective agent. The effects of single doses of 0, 0.125, 0.75, and 3.0 mg trimoprostil on intrauterine pressure were measured in a double-blind, crossover study in eight surgically sterile women. The 3 mg dose was not tolerated because of abdominal cramps. The other doses caused a dose-related increase in resting uterine tone and peak pressure with peak effect occurring between 30 and 60 minutes after administration with a duration of about 120 minutes. No effects on the frequency of uterine contractions occurred. Peak mean tone increased from 11.0 to 71.2 mm Hg (p less than 0.01) and peak pressure from 24.6 to 125.1 mm Hg (p less than 0.01) after placebo compared with the 1.5 mg dose. Adverse reactions included abdominal pain that correlated with an increase in intrauterine pressure and tone.